These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 4200058)

  • 1. [The relation between bacilli negative conversion rate and the number of combined sensitive antituberculous drugs in intermittent administration of rifampicin for severe pulmonary tuberculosis].
    Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M
    Kekkaku; 1973 Jul; 48(7):297-302. PubMed ID: 4200058
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rifampicin in the retreatment of severe cavitary pulmonary tuberculosis. I. Some considerations on the sputum conversion rate and the emergence of drug resistance].
    Baba H; Takahashi R; Azuma Y
    Kekkaku; 1971 Nov; 46(11):429-35. PubMed ID: 5004056
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifampin in the treatment of drug-resistant mycobacterium tuberculosis infections.
    Vall-Spinosa A; Lester W; Moulding T; Davidson PT; McClatchy JK
    N Engl J Med; 1970 Sep; 283(12):616-21. PubMed ID: 4988918
    [No Abstract]   [Full Text] [Related]  

  • 4. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
    Trébucq A; Rieder HL
    Int J Tuberc Lung Dis; 1998 Mar; 2(3):184-6. PubMed ID: 9526189
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bacteriological relapse among the previously treated advanced pulmonary tuberculosis patients whose sputum converted to negative by the rifampicin treatment, with special reference to the duration of rifampicin administration (author's transl)].
    Yamamoto M; Morishita M; Hirano Y; Nagata A; Yazaki M
    Kekkaku; 1974 Jul; 49(7):195-9. PubMed ID: 4214961
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens].
    Muratov VV; Pashkov IuN; Pospelov VV
    Probl Tuberk; 1981 Dec; (12):30-4. PubMed ID: 6801646
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of the therapeutic effects of secondary antituberculous drugs and evaluation of back-ground factors of the patients to the negative conversion of bacilli among the previously treated severe tuberculosis patients (author's transl)].
    Yamamoto M; Sassa H; Suzuki T; Morishita M; Nagata A
    Kekkaku; 1977 Aug; 52(8):399-404. PubMed ID: 410992
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rifampicin combined with ethambutol and other antitubercular drugs in the treatment of patients with pulmonary tuberculosis. Early results. I. Bacteriological evaluation].
    Masztalerz J
    Pneumonol Pol; 1976; 44(1):55-60. PubMed ID: 821043
    [No Abstract]   [Full Text] [Related]  

  • 9. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin in the treatment of resistant pulmonary tuberculosis.
    Wäre M; Lorenzen J
    Scand J Respir Dis Suppl; 1970; 72():113-9. PubMed ID: 4990617
    [No Abstract]   [Full Text] [Related]  

  • 11. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
    Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
    Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of tuberculosis patients with massive bacterial excretion].
    Gavril'ev SS; Vinokurova MK
    Probl Tuberk; 1997; (2):17-8. PubMed ID: 9235572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sputum positive conversion among retreatment cases with pulmonary tuberculosis converted to negative by the use of rifampicin (author's transl)].
    Ito F; Okochi T; Yamazaki M; Yamamoto Y; Kondo K; Konishiike J; Asahi T
    Kekkaku; 1979 Jan; 54(1):37-42. PubMed ID: 107360
    [No Abstract]   [Full Text] [Related]  

  • 14. [Follow-up observation on relapse of smear negative pulmonary tuberculosis after short-course chemotherapy].
    Xu WG; Gao Z; Fan BD
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):74-6. PubMed ID: 12783655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project].
    Wen S; Su Y; Zhang F
    Zhonghua Jie He He Hu Xi Za Zhi; 1996 Dec; 19(6):357-9. PubMed ID: 9596819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Direct genetic analysis of the rifampicin resistance of M. tuberculosis isolates in sputum samples].
    Generozov EV; Akopian TA; Vladimirskiĭ MA; Shipina LK; Irtuganova OA; Govorun VM
    Probl Tuberk Bolezn Legk; 2003; (4):49-52. PubMed ID: 12774423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled clinical trial on efficacy of 5-month regimens and whole course intermittent 6-month regimens in treating bacillary pulmonary tuberculosis].
    Chu N; Yan B; Zhu L
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jul; 21(7):388-91. PubMed ID: 11326873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative bacteriology in the clinical testing of new antituberculosis drugs.
    Wallace AT
    Tubercle; 1969 Mar; 50():Suppl:47-9. PubMed ID: 4990183
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bacteriologic test during rifampicin treatment].
    Ivaldy F
    Rev Tuberc Pneumol (Paris); 1969; 33(6):818-20. PubMed ID: 4989191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.